Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic a…
$162.56-1.09%
报价 2026-11-16
市值
$6.55B
EV
$7.76B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -16.0%
$109.18$193.61
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BLTEBelite Bio, Inc | $6.55B | -1.1% | – | 0% | – | – | – | |
| IMVTImmunovant, Inc. | $6.89B | -2.6% | -37.1% | 98.6% | – | – | – | |
| ORKAOruka Therapeutics, Inc. | $6.73B | -5.8% | – | 0% | – | – | – | |
| KODKodiak Sciences Inc. | $6.59B | -9.4% | +1783.3% | 0% | – | – | – | |
| IBRXImmunityBio, Inc. | $6.36B | -0.7% | +77.4% | 94.6% | – | – | – | |
| ARWRArrowhead Pharmaceuticals, Inc. | $6.25B | -7.5% | -34.0% | 100% | – | – | – | |
| LGNDLigand Pharmaceuticals, Inc. | $6.04B | -2.3% | +10.6% | 97.5% | 31.8x | 21.8x | 66.6x | |
| CAICaris Life Sciences, Inc. | $6.02B | -8.9% | +37.6% | 69.7% | 80.6x | 47.7x | 57.9x | |
| MIRMMirum Pharmaceuticals, Inc. | $5.98B | -2.6% | +39.2% | 81.7% | – | – | – | |
| 同行中位数 | – | – | +37.6% | 88.2% | 56.2x | 34.7x | 62.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。